Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories.
- R. Hayeshi, C. Hilgendorf, A. Ungell
- BiologyEuropean Journal of Pharmaceutical Sciences
- 18 December 2008
Lipid-based formulations for intestinal lymphatic delivery.
- C. O’Driscoll
- BiologyEuropean Journal of Pharmaceutical Sciences
- 1 June 2002
Pattern recognition receptors--molecular orchestrators of inflammation in inflammatory bowel disease.
- D. Walsh, J. McCarthy, C. O’Driscoll, S. Melgar
- Biology, MedicineCytokine & growth factor reviews
- 1 April 2013
Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
- Jianfeng Guo, W. Cheng, C. O’Driscoll
- Biology, ChemistryEuropean Journal of Pharmaceutical Sciences
- 11 April 2012
PEGylated gold nanoparticles: polymer quantification as a function of PEG lengths and nanoparticle dimensions
- K. Rahme, Lan Chen, R. Hobbs, M. Morris, C. O’Driscoll, J. Holmes
- Materials Science, Chemistry
- 2 April 2013
Au nanoparticles with diameters ranging between 15 and 170 nm have been synthesised in aqueous solution using a seed-mediated growth method, employing hydroxylamine hydrochloride as a reducing agent.…
Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance
- D. M. Mc Carthy, M. Malhotra, A. O’Mahony, J. Cryan, C. O’Driscoll
- BiologyPharmaceutical Research
- 1 April 2015
This review provides a comprehensive description of the design and formulation of these nanoparticles including the rationale behind individual approaches and the ability of currently available in-vitro BBB models to accurately predict the in- vivo performance of targeted nanoparticles is critically assessed.
Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?
- Jianfeng Guo, L. Bourré, D. Soden, G. O'sullivan, C. O’Driscoll
- BiologyBiotechnology Advances
- 1 July 2011
Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.
- B. M. Godinho, J. Ogier, R. Darcy, C. O’Driscoll, J. Cryan
- Biology, ChemistryMolecular Pharmaceutics
- 9 January 2013
The utility of modified β-CDs as efficient and safe siRNA delivery vectors for RNAi-based therapies for neuropsychiatric and neurodegenerative disorders is supported.
Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy.
- M. Walsh, M. Tangney, C. O’Driscoll
- Biology, ChemistryMolecular Pharmaceutics
- 8 September 2006
Comparisons with other cationic lipid and polymeric vectors demonstrates that C1K30-PEG transfects cells more efficiently than unpegylated poly-L-lysine and compares well to commercially available vectors.
Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
- C. O’Driscoll, B. Griffin
- Biology, ChemistryAdvanced Drug Delivery Reviews
- 17 March 2008
...
...